EPIGENE.COM

Serial Number 78935316
606

Registration Progress

Application Filed
Jul 21, 2006
Under Examination
Dec 18, 2007
Approved for Publication
Sep 5, 2007
Published for Opposition
Sep 25, 2007
Registered

Trademark Image

EPIGENE.COM

Basic Information

Serial Number
78935316
Filing Date
July 21, 2006
Published for Opposition
September 25, 2007
Abandonment Date
January 17, 2011
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jan 17, 2011
Classes
005

Rights Holder

Epigenesis Pharmaceuticals, LLC

99
Address
2009 Eastpark Boulevard
Cranbury, NJ 08512

Ownership History

Epigenesis Pharmaceuticals, LLC

Original Applicant
99
Cranbury, NJ

Epigenesis Pharmaceuticals, LLC

Owner at Publication
99
Cranbury, NJ

Legal Representation

Attorney
Albert P. Halluin

USPTO Deadlines

All Deadlines Cleared

All 4 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

32 events
Date Code Type Description Documents
Jan 18, 2011 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Jan 17, 2011 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
May 26, 2010 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
May 25, 2010 EX5G S SOU EXTENSION 5 GRANTED Loading...
May 17, 2010 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 17, 2010 EXT5 S SOU EXTENSION 5 FILED Loading...
Dec 9, 2009 EX4G S SOU EXTENSION 4 GRANTED Loading...
Dec 2, 2009 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 2, 2009 EXT4 S SOU EXTENSION 4 FILED Loading...
Jun 30, 2009 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jun 30, 2009 EX3G S SOU EXTENSION 3 GRANTED Loading...
Jun 8, 2009 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 8, 2009 EXT3 S SOU EXTENSION 3 FILED Loading...
Dec 1, 2008 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 1, 2008 EXT2 S SOU EXTENSION 2 FILED Loading...
Dec 1, 2008 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jun 4, 2008 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 4, 2008 EXT1 S SOU EXTENSION 1 FILED Loading...
Jun 4, 2008 EX1G S SOU EXTENSION 1 GRANTED Loading...
Dec 18, 2007 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 25, 2007 PUBO A PUBLISHED FOR OPPOSITION Loading...
Sep 5, 2007 NPUB O NOTICE OF PUBLICATION Loading...
Aug 20, 2007 ALIE A ASSIGNED TO LIE Loading...
Aug 20, 2007 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Jul 5, 2007 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 28, 2007 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 28, 2007 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jun 28, 2007 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 29, 2006 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 29, 2006 GNRT F NON-FINAL ACTION E-MAILED Loading...
Dec 17, 2006 DOCK D ASSIGNED TO EXAMINER Loading...
Jul 26, 2006 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ards), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (svt), adenosine stress tests, infantile respiratory distress syndrome (infantile rds), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (copd), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
".COM"